Sodium cellulose phosphate API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Sodium cellulose phosphate API 9038-41-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Sodium cellulose phosphate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Sodium cellulose phosphate
- Synonyms:
- Cellulose dihydrogen phosphate, disodium salt , Cellulose disodium phosphate , Cellulose sodium phosphate
- Cas Number:
- 9038-41-9
- DrugBank number:
- DB06776
- Unique Ingredient Identifier:
- E6S1NJ4Y5Q
General Description:
Sodium cellulose phosphate, identified by CAS number 9038-41-9, is a notable compound with significant therapeutic applications. Sodium cellulose phosphate is used to treat hypercalcemia and hypercalciuria. It has been used to prevent kidney stones. This compound is an ion-exchange resin that can not be absorbed by the body. However, it can be used to restore normal intestinal calcium absorption.
Mechanism of Action:
Sodium cellulose phosphate functions by: When it is taken orally, it stays in the intestine and it binds strongly to calcium inhibiting its intestinal absorption. From there, inhibition is caused due to the lower intraluminal calcium levels, which is typically available for absorption. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Categories:
Sodium cellulose phosphate is categorized under the following therapeutic classes: Biopolymers, Calcium Binder, Calcium Chelating Activity, Carbohydrates, Cation Exchange Resins, Compounds used in a research, industrial, or household setting, Drugs for Treatment of Hypercalcemia, Glucans, Macromolecular Substances, Polymers, Polysaccharides. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Sodium cellulose phosphate is a type of Gastrointestinal Agents
Gastrointestinal Agents belong to the pharmaceutical API category that focuses on treating disorders and ailments related to the digestive system. These agents play a crucial role in addressing various gastrointestinal conditions, such as acid reflux, ulcers, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD).
One of the key types of gastrointestinal agents is proton pump inhibitors (PPIs), which work by reducing the production of stomach acid. PPIs help in treating conditions like gastroesophageal reflux disease (GERD) and peptic ulcers. Another essential class of agents is antacids, which neutralize excessive stomach acid, providing relief from heartburn and indigestion.
Gastrointestinal agents also include antispasmodics that alleviate abdominal cramps and spasms associated with conditions like IBS. These drugs work by relaxing the smooth muscles of the digestive tract. Additionally, there are drugs categorized as laxatives that aid in relieving constipation by promoting bowel movements.
Moreover, certain gastrointestinal agents act as antiemetics, effectively reducing nausea and vomiting. These drugs are particularly useful for patients undergoing chemotherapy or experiencing motion sickness.
Pharmaceutical companies develop and manufacture a wide range of gastrointestinal agents in various forms, including tablets, capsules, suspensions, and injections. These agents are typically formulated using active pharmaceutical ingredients (APIs) and other excipients to ensure their efficacy and safety.
In conclusion, gastrointestinal agents form a vital category of pharmaceutical APIs, providing relief from digestive disorders and improving overall gastrointestinal health. The availability of diverse agents catering to different conditions ensures that patients can receive targeted treatment for their specific gastrointestinal needs.
